FMI Report: The Helicobacter pylori infection treatment industry is expected to reach US$1.26 billion from 2023 to 2033, with a compound annual growth rate of 7.04%

Helicobacter pylori infection treatment industry

The global Helicobacter pylori infection treatment industry is expected to reach US$638.3 million in 2023, with a compound annual growth rate (CAGR) of 7.04% from 2023 to 2033, reaching US$1.26 billion. The spread of such infections can be attributed to a variety of factors, including lack of adequate water supply, poor sanitation, large populations and poor hygiene. One of the factors influencing the growth of the Helicobacter pylori diagnostics market is the increasing awareness about Helicobacter pylori infection.

The availability and affordability of antibiotics and faster processing times will increase antibiotic use and the need for pre- and post-surveillance testing. Additionally, rising rates of Helicobacter pylori infection, demand for early symptom diagnosis, and technological advancements in diagnostic methods are expected to drive overall growth during the forecast period.

Get the latest updated market report as a sample! https://www.futuremarketinsights.com/reports/sample/rep-gb-16291

The main drivers of the industry are the increasing prevalence of infectious diseases and increasing public awareness of infections. Tuberculosis, chlamydia, gonorrhea, other sexually transmitted diseases (STDs), stomach flu (gastroenteritis), and bladder infections are the most common viral infections (UTIs). North America is expected to dominate the global Helicobacter pylori diagnostics industry over the forecast period. This increase may be related to factors such as increased disease transmission, increased awareness of infectious diseases, and the launch of new products.

Key points of market research:

• The global Helicobacter pylori treatment market will nearly double from 2023 to 2033
• By 2023, Europe is expected to be the second-highest country for Helicobacter pylori sales, accounting for 30% of revenue.
• In terms of total revenue, hospitals and diagnostic laboratories accounted for more than 82% of the industry share in 2021.
• The global Helicobacter pylori infection market is estimated to be worth US$1.26 billion
• The global Helicobacter pylori infection market is estimated to be worth USD 638.3 million

“As the prevalence of chronic diseases rises, the demand for H. pylori treatments is increasing, paving the way for new treatments and therapies,” said an analyst at FMI.

Contact our analysts and get all your questions answered! https://www.futuremarketinsights.com/ask-question/rep-gb-16291

market competition:

• fatone pharmaceutical co., ltd.
• Hongshan Biopharmaceutical
• Takeda Pharmaceutical
• AbbVie
• cumberland pharmaceutical co.
• Eisai Co., Ltd.
• Bio-Rad Laboratories
• F.Hoffman-LaRoche
• alpha lab
• Black & Decker
• In May 2022, Biomerica, Inc. received CE mark for its Helicobacter pylori hp+detect diagnostic test. Following product registration in each country of sale, the company plans to market and sell its hp+Detect diagnostic test in the European Union (EU) and other international markets.
• Otsuka launches QuickNavi^{TM value}-H. Helicobacter pylori rapid detection kit, April 2021. This diagnostic kit uses immunochromatographic technology to determine the presence of Helicobacter pylori antigens in stool samples.
• In July 2022, Bio Rad launched Platelia H. pylori IgG, an immunoenzymatic assay for the qualitative determination of IgG antibodies. Serology is a non-invasive, sophisticated and simple method of determining H. pylori infection. To assess the quality of IgG antibodies, the Platelia Helicobacter pylori IgG immunoenzymatic assay was used.

If you have any questions, please feel free to contact our analysts! https://www.futuremarketinsights.com/ask-question/rep-gb-16291

Key segments profiled in the Helicobacter pylori Infection Treatment industry industry survey:

Press treatment:

• Bismuth quadruple therapy
• Concomitant treatment
• Levofloxacin triple therapy
• bismuth therapy
• high dose dual therapy

By application:

• Hospital
• diagnostic laboratory
• Clinic

By region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

About Future Market Insights (IMF)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award winner, member of the Greater New York Chamber of Commerce) provides deep insights into the drivers driving market demand. FMI is a leading global provider of market intelligence, consulting services, consulting and events for the packaging, food and beverage, consumer technology, healthcare, industrial and chemicals markets. FMI has a large team of more than 5,000 analysts worldwide, providing global, regional and local expertise on diverse sectors and industry trends in more than 110 countries.

contact us:

Nandini Singh Savarani

Future Market Insights Company
Christiana Inc., 200 Continental Avenue,
Room 401, Newark, DE – 19713, United States
Phone: +1-845-579-5705
Sales enquiry:

sales@futuremarketinsights.com
website: https://www.futuremarketinsights.com
LinkedIn | Twitter| Blog | YouTube